Dutch preclinical biotech targeting cellular senescence for late-stage cancer and chronic disease.
| Date | Round | Amount |
|---|---|---|
| Sep 2022 | Seed Utrecht biotech Cleara raised a 2.5M dollar seed round led by Apollo Health Ventures, with Curie Capital, ROM Utrecht Region and Longevity Tech Fund, to advance its senescence-targeting compounds. | $2.6M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.